Bacillus subtilis: stool frequency and constipation symptoms
Findings from studies of BS50 and treated BG01-4 for stool and constipation symptoms.
Key points
- In healthy adults with mild digestive complaints, no significant advantage of BS50 over placebo was found for stool frequency or consistency over six weeks. On average, stools were regular before the study. [1] See the evidence 1 2
- In adults with long-standing bowel complaints without IBS, the constipation symptom score decreased over four weeks by 33% with heat-treated BG01-4 and 15% with placebo. Certainty in the result is very low. [2] See the evidence 1
Practical guide
Check the findings and their applicability to your situation.
Two studies assessed different strains, groups and stool measures.
Key points
Why these conclusions
Studies of stool and constipation
Healthy adults with mild complaints took 2 billion CFU of BS50 daily for six weeks. No significant differences in changes in stool frequency and form compared with placebo were found; at baseline, stools were on average regular and of normal consistency, and certainty is low — 2 out of 4. [1]
In a study of adults with long-standing bowel complaints without IBS, one 1 g sachet of BG01-4 daily was compared with placebo for four weeks. The main analysis showed a 33% versus 15% reduction in the constipation score; a supplementary table gives different values, and certainty is very low — 1 out of 4. [2]
No significant advantage over placebo was found for stool frequency. At baseline the averages were 8.6 versus 7.9 times per week, and at week six 9.4 versus 9.3. Comparison of changes at week six: p=0.42.
| Parameter | Data |
|---|---|
| Result | No significant advantage over placebo was found for stool frequency. At baseline the averages were 8.6 versus 7.9 times per week, and at week six 9.4 versus 9.3. Comparison of changes at week six: p=0.42. |
| Participants | 76 healthy adults aged 30–65 with mild complaints of bloating, belching or gas; 38 people per group. All completed the study. |
| Form | BS50: capsule containing spores |
| Dose | 2 billion CFU in one capsule daily with the largest meal |
| Dose basis | 2 billion CFU in one capsule daily with the largest meal |
| Comparison | Placebo capsule containing maltodextrin |
| Duration | 6 weeks |
| Certainty | 2/4: One small six-week study; participants kept a stool diary. Before the course, stools were on average regular and of normal consistency; chronic constipation was not a condition for participation. |
| Body of evidence | 1 publication described |
| Sources | [1] |
No significant advantage over placebo was found for stool consistency. Mean Bristol stool scale score: 3.9 → 3.8 on BS50 and 3.6 → 3.7 on placebo; overall analysis of changes — p=0.29.
| Parameter | Data |
|---|---|
| Result | No significant advantage over placebo was found for stool consistency. Mean Bristol stool scale score: 3.9 → 3.8 on BS50 and 3.6 → 3.7 on placebo; overall analysis of changes — p=0.29. |
| Participants | 76 healthy adults aged 30–65 with mild complaints of bloating, belching or gas; 38 people per group. All completed the study. |
| Form | BS50: capsule containing spores |
| Dose | 2 billion CFU in one capsule daily with the largest meal |
| Dose basis | 2 billion CFU in one capsule daily with the largest meal |
| Comparison | Placebo capsule containing maltodextrin |
| Duration | 6 weeks |
| Certainty | 2/4: One small six-week study; participants kept a stool diary. Before the course, stools were on average regular and of normal consistency; chronic constipation was not a condition for participation. |
| Body of evidence | 1 publication described |
| Sources | [1] |
In the main analysis, the authors reported a 33% reduction in constipation symptoms on the questionnaire with BG01-4 and a 15% reduction with placebo.
| Parameter | Data |
|---|---|
| Result | In the main analysis, the authors reported a 33% reduction in constipation symptoms on the questionnaire with BG01-4 and a 15% reduction with placebo. |
| Participants | Adults aged 18–75 with self-reported long-standing bowel complaints; IBS was excluded. A total of 80 people were allocated under the study design (42 and 38), and 67 were included in the analysis (34 and 33). |
| Form | BG01-4: heat-treated bacterial powder in a sachet with maltodextrin |
| Dose | One 1 g sachet daily; contents added to 250 mL of water, juice or food |
| Dose basis | One 1 g sachet daily; contents added to 250 mL of water, juice or food |
| Comparison | Placebo sachet with maltodextrin |
| Duration | 4 weeks |
| Certainty | 1/4: One preliminary study; 13 of 80 allocated participants did not complete the protocol. The main figure and a supplementary analysis table report different magnitudes of improvement in constipation. The text also contains errors in group sizes. These discrepancies explain the very low certainty. |
| Body of evidence | 1 publication described |
| Sources | [2] |
Information from the source
In a study of 5 billion CFU of MB40 daily, adverse events were reported in both groups. Those possibly related to the supplement included constipation, abdominal discomfort, diarrhea, gas and dry mouth; they had resolved by the end of the study. In a separate tolerability study of 10 billion CFU of MB40 daily, one participant experienced vomiting and chills, which the authors considered probably related to intake. They resolved within 31 hours. In the R0179 study, one participant in the 10 billion CFU group discontinued after itching and skin redness; a causal relationship was not established. In people with severe illness, weakened immunity or a central venous catheter, live probiotics require individual medical assessment because of the risk of infection. The FDA issued a separate warning for hospitalized preterm infants. This information applies to probiotics in general, not to an established infection rate for each B. subtilis strain. [3] [4] [5] [6] [7]
Information from the source
| Name | Description | Sources |
|---|---|---|
| Live strains in capsules | BS50, MB40, R0179 and CU1 are different strains with their own studies. On the label, the strain code, CFU count through the end of shelf life and storage conditions matter. A higher CFU count alone does not mean a greater effect. | [1] [3] [6] [8] [4] |
| BG01-4 after heating | The study used a sachet containing 1 g of powder after heat treatment. The article also reports 5 billion CFU, but does not explain whether this figure refers to the state before or after heating. It is therefore not presented here as a dose of live bacteria. | [2] |
| Food cultures | Natto and other fermented foods have their own food strains. Their presence in a product does not establish an effect of BS50 or MB40. Preparation can change the number of live bacteria; in a natto study, boiling reduced it. | [9] [10] [11] [12] [13] |
More details
Form and safety
BG01-4 was studied after heat treatment; the CFU count reported in the article is not defined as a dose of live bacteria. In people with severe illness or weakened immunity, live probiotics require individual medical assessment. [3] [4] [5] [6] [7] [2] [9] [12] [13] [10] [11] [8] [1]
Sources
- The probiotic Bacillus subtilis BS50 decreases gastrointestinal symptoms in healthy adults: a randomized, double-blind, placebo-controlled trial. https://pubmed.ncbi.nlm.nih.gov/36269141/
- Bacillus Subtilis (BG01-4(TM)) Improves Self-Reported Symptoms for Constipation, Indigestion, and Dyspepsia: A Phase 1/2A Randomized Controlled Trial. https://pubmed.ncbi.nlm.nih.gov/37960143/
- A Randomized, Double-blind, Placebo-controlled, Parallel Study Evaluating the Efficacy of Bacillus subtilis MB40 to Reduce Abdominal Discomfort, Gas, and Bloating. https://pubmed.ncbi.nlm.nih.gov/31719214/
- Probiotics — Health Professional Fact Sheet (NIH ODS). https://ods.od.nih.gov/factsheets/Probiotics-HealthProfessional/
- FDA Raises Concerns About Probiotic Products Sold for Use in Hospitalized Preterm Infants. https://www.fda.gov/news-events/press-announcements/fda-raises-concerns-about-probiotic-products-sold-use-hospitalized-preterm-infants
- Evaluation of Bacillus subtilis R0179 on gastrointestinal viability and general wellness: a randomised, double-blind, placebo-controlled trial in healthy adults. https://pubmed.ncbi.nlm.nih.gov/25062611/
- Safety Assessment of Bacillus subtilis MB40 for Use in Foods and Dietary Supplements. https://pubmed.ncbi.nlm.nih.gov/33668992/
- Probiotic strain Bacillus subtilis CU1 stimulates immune system of elderly during common infectious disease period: a randomized, double-blind placebo-controlled study. https://pubmed.ncbi.nlm.nih.gov/26640504/
- Whole-Genome Sequencing and Comparative Genome Analysis of Bacillus subtilis Strains Isolated from Non-Salted Fermented Soybean Foods. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0141369
- Characterization of Bacillus subtilis strains in Thua nao, a traditional fermented soybean food in northern Thailand. https://doi.org/10.1111/j.1472-765X.2006.01966.x
- Genotyping of starter cultures of Bacillus subtilis and Bacillus pumilus for fermentation of African locust bean (Parkia biglobosa) to produce Soumbala. https://pubmed.ncbi.nlm.nih.gov/14698101/
- Co-production of surfactin and a novel bacteriocin by Bacillus subtilis subsp. subtilis H4 isolated from Bikalga, an African alkaline Hibiscus sabdariffa seed fermented condiment. https://www.sciencedirect.com/science/article/pii/S0168160513000421
- Treatment of natto, a fermented soybean preparation, to prevent excessive plasma vitamin K concentrations in patients taking warfarin. https://pubmed.ncbi.nlm.nih.gov/17190098/
Methodology: Subpages evidence-led supplement pipeline v1